EPI-001 (EPI001; EPI 001) is a novel, potent small-molecule antagonist of AR-androgen receptor N-terminal domain (NTD) with potential antineoplastic activity.

ACP-105 (ACP105; ACP 105) is a novel, nonsteroidal and orally bioactive SARM (selective androgen receptor modulator) that has been investigated for the treatment of age-related cognitive decline.

Darolutamide (formerly known as BAY-1841788; ODM-201; BAY1841788; Nubeqa) is a novel and potent androgen receptor (AR) antagonist with potential antitumor activity.

Proxalutamide (GT0918; GT-0918) is a novel, oral and potent androgen receptor/AR antagonist or nonsteroidal antiandrogen (NSAA).

Epiandrosterone [also known as 3β-androsterone, Epi (17-ketosteroid epiandrosterone)] is a naturally occuring/endogenous steroid hormone with weak androgenic activity.

AZD3514 (AZD-3514; AZD 3514) is a novel, potent and orally bioavailable androgen receptor downregulator with potential anticancer activity.

Megestrol acetate (formerly BDH1298, SC10363; BDH-1298; SC-10363; Megace; Ovaban; Pallace; Maygace; Megestil; Niagestin) is a synthetic progestogen derivative that has been approved for use in the treatment of breast cancer and loss of appetite.

RU-58841 is a new specific a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism.

Flutamide (also known as SCH13521; SCH-13521; trade names: Flucinom; Flugerel; Niftolid; Flutan; Oncosal etc.), a toluidine derivative, is a potent non-steroidal antiandrogen drug (AR antagonist) with potential anticancer activity. It is mainly used for the treatment of prostate cancer. Flutamide can be transformed into an active metablolite that binds to androgen receptor with a Ki […]

Apalutamide (formerly JNJ56021927; ARN509; JNJ-56021927; ARN-509; trade name Erleada), an approved anticancer drug, is a potent, selective and competitive, orally bioavailable AR/androgen receptor inhibitor with an IC50 of 16 nM in a cell-free assay.